News organisations gather in Paris to collaborate on securing media provenance

It has never been more important to safeguard authentic news media, say the organisers.

It has never been more important to safeguard authentic news media, say the organisers.
Anglais
02/05/2026 05:30
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat® KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for p...

Agence France-Presse and Getty Images sign multi-year renewal of longstanding global content partnership

Long-term global partnership continues to provide newsrooms around the world with unrivalled visual coverage of news, sport and entertainment.

Long-term global partnership continues to provide newsrooms around the world with unrivalled visual coverage of news, sport and entertainment.
Anglais

AFP becomes Alliance magazine official partner

Agence France-Presse (AFP) is pleased to announce a new partnership with Alliance magazine, a leading global media platform serving decision-makers in the philanthropic sector.

Agence France-Presse (AFP) is pleased to announce a new partnership with Alliance magazine, a leading global media platform serving decision-makers in the philanthropic sector.
Anglais
12/15/2025 13:03
Ant Group Announces Major Upgrades to Its 15-Million-MAU AI Health App AQ Amid Wider Push into Health Sector

Ant Group today announced major upgrades to its AI health app AQ, with a new Chinese name “Ant A-Fu.” The character “Fu” conveys good wishes and well-being, reflecting the app’s goal to promote better health and quality of life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215203213/en/Ant Group’s AI health app AQ features three core capabilities: health Q&A, AI health companion, and integrated health services. The upgraded ...

12/15/2025 13:00
Copeland and Daikin Cooperation Brings Solutions to European Customers

Copeland and Daikin, two global leaders in heating, ventilation and air conditioning (HVAC) solutions, today announced the expansion of their existing joint venture into Europe. Through this cooperation, the companies will introduce advanced inverter swing rotary compressors, power electronics and controls designed specifically for European residential heat pumps. This collaboration underscores both companies’ commitment to accelerate the energy transition, with heat pumps recognized by industr...

02/05/2026 06:30
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing

Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay conclu...

12/15/2025 13:05
Novotech Issues White Paper to Help Sponsors Strengthen Early-Phase Oncology Strategy and Execution

Novotech, a leading global full-service clinical research organization (CRO) and scientific advisory company, has released a new white paper, Early-Phase Oncology – Clinical Research Landscape and CRO Enablers (2025), offering in-depth analysis of the key drivers shaping early-phase oncology development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215843975/en/ With approximately 60% of oncology agents progressing from Phase I ...